Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2004 Oct;75(10):1411–1415. doi: 10.1136/jnnp.2003.025171

A follow up study of patients with paraneoplastic neurological disease in the United Kingdom

P Candler 1, P Hart 1, M Barnett 1, R Weil 1, J Rees 1
PMCID: PMC1738729  PMID: 15377687

Abstract

Objectives: To examine the range of clinical phenotypes, tumour associations, relevant investigations, response to therapy and outcome in a large series of non-selected patients with paraneoplastic neurological disease (PND) affecting the central nervous system (CNS) in the United Kingdom.

Methods: Data were obtained on patients either through direct referral or through the British Neurological Surveillance Unit (BNSU) from February 2000 to January 2001. Physicians were asked to supply information about age and sex of patients, presenting neurological syndromes, the basis of the diagnosis of PND, any associated malignancy, and treatment. Case notes were reviewed and follow up data obtained where possible one year after notification.

Results: A total of 63 patients (48 females, 15 males) were identified, 48 through the BNSU and 15 through direct referral. Of these 52 were diagnosed as having definite PND, 10 probable PND, and 1 possible PND. The median age of onset of PND was 66 years (range 30–80 years) and only 7 patients (11%) were less than 50 years at presentation. In 53 patients (84%) the PND preceded the diagnosis of cancer. Paraneoplastic sensory neuronopathy, paraneoplastic encephalomyelitis, and paraneoplastic cerebellar degeneration (PCD) were the most common syndromes reported. The benefit of magnetic resonance imaging in the diagnosis of the disease was limited, while fluorodeoxyglucose positron emission tomography was shown to be useful for the detection of an occult malignancy in 10 out of 14 patients. Antineuronal antibodies were positive in 44/57 (77%) of cases. The following tumours were diagnosed: small cell lung cancer (30%), breast cancer (14%), ovarian cancer (8%), non-small cell lung cancer (8%), Hodgkin's lymphoma (6%), other (16%). With the exception of PCD associated with mesothelioma all other tumours diagnosed in these patients had been previously documented as being associated with PND. Only treatment of the tumour was found to be associated with a stable or improved neurological outcome at last follow up (Fisher‘s exact test = 4.7, p<0.03). Median survival time was 43 months (95% CI 28 to 57) from onset of neurological disease as calculated using the Kaplan–Meier survival analysis.

Conclusions: PND has a striking female preponderance usually affecting patients in their sixth decade and above. The median survival in our study was 43 months. The majority of patients with PND are not known to have cancer at the time of diagnosis. Our study confirms the importance of diagnosing and treating the underlying tumour.

Full Text

The Full Text of this article is available as a PDF (73.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson N. E., Rosenblum M. K., Graus F., Wiley R. G., Posner J. B. Autoantibodies in paraneoplastic syndromes associated with small-cell lung cancer. Neurology. 1988 Sep;38(9):1391–1398. doi: 10.1212/wnl.38.9.1391. [DOI] [PubMed] [Google Scholar]
  2. Anderson N. E., Rosenblum M. K., Posner J. B. Paraneoplastic cerebellar degeneration: clinical-immunological correlations. Ann Neurol. 1988 Oct;24(4):559–567. doi: 10.1002/ana.410240413. [DOI] [PubMed] [Google Scholar]
  3. Croft P. B., Henson R. A., Urich H., Wilkinson P. C. Sensory neuropathy with bronchial carcinoma: a study of four cases showing serological abnormalities. Brain. 1965 Sep;88(3):501–514. doi: 10.1093/brain/88.3.501. [DOI] [PubMed] [Google Scholar]
  4. Dalmau J., Furneaux H. M., Gralla R. J., Kris M. G., Posner J. B. Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer--a quantitative western blot analysis. Ann Neurol. 1990 May;27(5):544–552. doi: 10.1002/ana.410270515. [DOI] [PubMed] [Google Scholar]
  5. Dalmau J., Graus F., Rosenblum M. K., Posner J. B. Anti-Hu--associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore) 1992 Mar;71(2):59–72. doi: 10.1097/00005792-199203000-00001. [DOI] [PubMed] [Google Scholar]
  6. Elrington G. M., Murray N. M., Spiro S. G., Newsom-Davis J. Neurological paraneoplastic syndromes in patients with small cell lung cancer. A prospective survey of 150 patients. J Neurol Neurosurg Psychiatry. 1991 Sep;54(9):764–767. doi: 10.1136/jnnp.54.9.764. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Faris M., Abraham J., Barrett-Lee P. A patient with breast cancer and paraneoplastic cerebellar syndrome associated with anti-Purkinje cell antibodies: response to CMF chemotherapy. Clin Oncol (R Coll Radiol) 1998;10(3):202–203. doi: 10.1016/s0936-6555(98)80072-1. [DOI] [PubMed] [Google Scholar]
  8. Graus F., Keime-Guibert F., Reñe R., Benyahia B., Ribalta T., Ascaso C., Escaramis G., Delattre J. Y. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain. 2001 Jun;124(Pt 6):1138–1148. doi: 10.1093/brain/124.6.1138. [DOI] [PubMed] [Google Scholar]
  9. Gultekin S. H., Rosenfeld M. R., Voltz R., Eichen J., Posner J. B., Dalmau J. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain. 2000 Jul;123(Pt 7):1481–1494. doi: 10.1093/brain/123.7.1481. [DOI] [PubMed] [Google Scholar]
  10. Luque F. A., Furneaux H. M., Ferziger R., Rosenblum M. K., Wray S. H., Schold S. C., Jr, Glantz M. J., Jaeckle K. A., Biran H., Lesser M. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol. 1991 Mar;29(3):241–251. doi: 10.1002/ana.410290303. [DOI] [PubMed] [Google Scholar]
  11. Peterson K., Rosenblum M. K., Kotanides H., Posner J. B. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology. 1992 Oct;42(10):1931–1937. doi: 10.1212/wnl.42.10.1931. [DOI] [PubMed] [Google Scholar]
  12. Rees J. H., Hain S. F., Johnson M. R., Hughes R. A., Costa D. C., Ell P. J., Keir G., Rudge P. The role of [18F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders. Brain. 2001 Nov;124(Pt 11):2223–2231. doi: 10.1093/brain/124.11.2223. [DOI] [PubMed] [Google Scholar]
  13. Shams'ili Setareh, Grefkens Joost, de Leeuw Bertie, van den Bent Martin, Hooijkaas Herbert, van der Holt Bronno, Vecht Charles, Sillevis Smitt Peter. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain. 2003 Jun;126(Pt 6):1409–1418. doi: 10.1093/brain/awg133. [DOI] [PubMed] [Google Scholar]
  14. Sillevis Smitt Peter, Grefkens Joost, de Leeuw Bertie, van den Bent Martin, van Putten Wim, Hooijkaas Herbert, Vecht Charles. Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol. 2002 Jun;249(6):745–753. doi: 10.1007/s00415-002-0706-4. [DOI] [PubMed] [Google Scholar]
  15. Stourac P., Kadanka Z., Palyza V. Paraneoplastic neurological syndromes - patients' cohort profile in the Czech Republic. Acta Neurol Scand. 2001 Aug;104(2):72–77. doi: 10.1034/j.1600-0404.2001.104002072.x. [DOI] [PubMed] [Google Scholar]
  16. Sutton I. J., Fursdon Davis C. J., Esiri M. M., Hughes S., Amyes E. R., Vincent A. Anti-Yo antibodies and cerebellar degeneration in a man with adenocarcinoma of the esophagus. Ann Neurol. 2001 Feb;49(2):253–257. doi: 10.1002/1531-8249(20010201)49:2<253::aid-ana47>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  17. Suzuki M., Kimura H., Tachibana I., Fujimura H., Nakatsuji Y., Sugai F., Naba I., Nakamori M., Morishita H., Arai T. Improvement of anti-Hu-associated paraneoplastic sensory neuropathy after chemoradiotherapy in a small cell lung cancer patient. Intern Med. 2001 Nov;40(11):1140–1143. doi: 10.2169/internalmedicine.40.1140. [DOI] [PubMed] [Google Scholar]
  18. Voltz R., Gultekin S. H., Rosenfeld M. R., Gerstner E., Eichen J., Posner J. B., Dalmau J. A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N Engl J Med. 1999 Jun 10;340(23):1788–1795. doi: 10.1056/NEJM199906103402303. [DOI] [PubMed] [Google Scholar]
  19. de la Sayette V., Bertran F., Honnorat J., Schaeffer S., Iglesias S., Defer G. Paraneoplastic cerebellar syndrome and optic neuritis with anti-CV2 antibodies: clinical response to excision of the primary tumor. Arch Neurol. 1998 Mar;55(3):405–408. doi: 10.1001/archneur.55.3.405. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES